Incyte
Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology
Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte